CL2022003578A1 - Fusiones heterodiméricas de relaxina y usos de las mismas - Google Patents
Fusiones heterodiméricas de relaxina y usos de las mismasInfo
- Publication number
- CL2022003578A1 CL2022003578A1 CL2022003578A CL2022003578A CL2022003578A1 CL 2022003578 A1 CL2022003578 A1 CL 2022003578A1 CL 2022003578 A CL2022003578 A CL 2022003578A CL 2022003578 A CL2022003578 A CL 2022003578A CL 2022003578 A1 CL2022003578 A1 CL 2022003578A1
- Authority
- CL
- Chile
- Prior art keywords
- relaxin
- heterodimeric
- treatment
- fusions
- fusion polypeptides
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 4
- 102000003743 Relaxin Human genes 0.000 title abstract 3
- 108090000103 Relaxin Proteins 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 101001091088 Homo sapiens Prorelaxin H2 Proteins 0.000 abstract 1
- 102100034949 Prorelaxin H2 Human genes 0.000 abstract 1
- -1 host cells Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040250P | 2020-06-17 | 2020-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003578A1 true CL2022003578A1 (es) | 2023-06-09 |
Family
ID=76584509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003578A CL2022003578A1 (es) | 2020-06-17 | 2022-12-15 | Fusiones heterodiméricas de relaxina y usos de las mismas |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11795205B2 (https=) |
| EP (1) | EP4168434A1 (https=) |
| JP (2) | JP7797423B2 (https=) |
| KR (1) | KR20230024994A (https=) |
| CN (1) | CN115916813B (https=) |
| AR (1) | AR125007A1 (https=) |
| AU (3) | AU2021290997C1 (https=) |
| BR (1) | BR112022025019A2 (https=) |
| CA (1) | CA3186143A1 (https=) |
| CL (1) | CL2022003578A1 (https=) |
| CO (1) | CO2023000038A2 (https=) |
| CR (1) | CR20230015A (https=) |
| EC (1) | ECSP23002960A (https=) |
| IL (1) | IL298786A (https=) |
| MX (1) | MX2022016340A (https=) |
| TW (1) | TWI899263B (https=) |
| WO (1) | WO2021255127A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118510536A (zh) | 2021-11-11 | 2024-08-16 | 泰克托尼治疗股份有限公司 | 松弛素-2融合蛋白类似物及其使用方法 |
| CA3252059A1 (en) | 2022-05-07 | 2025-07-07 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Relaxin fusion protein or analogue and its medical use |
| WO2024015634A2 (en) * | 2022-07-15 | 2024-01-18 | Nutcracker Therapeutics, Inc. | Mrna therapies including sirp-alpha |
| EP4630036A1 (en) | 2022-12-09 | 2025-10-15 | Astrazeneca AB | Dosing regimens using heterodimeric relaxin fusions |
| CN120813595A (zh) | 2023-03-03 | 2025-10-17 | 阿斯利康(瑞典)有限公司 | 包含异源二聚体松弛素融合蛋白的药物制剂及其用途 |
| AU2024270919A1 (en) | 2023-05-18 | 2026-01-15 | Tectonic Operating Company, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US8389475B2 (en) | 2009-08-10 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Relaxin analogs |
| ES2758994T3 (es) * | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| RU2014103288A (ru) * | 2011-07-01 | 2015-08-10 | Байер Интеллектчуал Проперти Гмбх | Слитые полипептиды релаксина и их применение |
| BR112014010580B1 (pt) * | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| AR094147A1 (es) | 2012-12-27 | 2015-07-15 | Bayer Pharma Aktiengellschaft | Polipeptidos de fusion con actividad de relaxina y sus usos |
| CA3244731A1 (en) * | 2014-05-28 | 2025-11-29 | Zymeworks Bc Inc. | Modified antigen binding polypeptide constructs and uses thereof |
| PT3387019T (pt) * | 2015-12-09 | 2022-01-14 | Scripps Research Inst | Proteínas de fusão de imunoglobulina de relaxina e métodos de uso |
| EP3574004A1 (en) * | 2017-01-25 | 2019-12-04 | Medimmune, LLC | Relaxin fusion polypeptides and uses thereof |
-
2021
- 2021-06-16 CA CA3186143A patent/CA3186143A1/en active Pending
- 2021-06-16 US US17/348,825 patent/US11795205B2/en active Active
- 2021-06-16 EP EP21734103.1A patent/EP4168434A1/en active Pending
- 2021-06-16 WO PCT/EP2021/066309 patent/WO2021255127A1/en not_active Ceased
- 2021-06-16 AU AU2021290997A patent/AU2021290997C1/en active Active
- 2021-06-16 CR CR20230015A patent/CR20230015A/es unknown
- 2021-06-16 BR BR112022025019A patent/BR112022025019A2/pt unknown
- 2021-06-16 CN CN202180042080.5A patent/CN115916813B/zh active Active
- 2021-06-16 KR KR1020237001632A patent/KR20230024994A/ko active Pending
- 2021-06-16 MX MX2022016340A patent/MX2022016340A/es unknown
- 2021-06-16 JP JP2022577390A patent/JP7797423B2/ja active Active
- 2021-06-16 IL IL298786A patent/IL298786A/en unknown
- 2021-06-17 AR ARP210101647A patent/AR125007A1/es unknown
- 2021-06-17 TW TW110122051A patent/TWI899263B/zh active
-
2022
- 2022-12-15 CL CL2022003578A patent/CL2022003578A1/es unknown
-
2023
- 2023-01-03 CO CONC2023/0000038A patent/CO2023000038A2/es unknown
- 2023-01-16 EC ECSENADI20232960A patent/ECSP23002960A/es unknown
- 2023-07-01 US US18/346,205 patent/US12187774B2/en active Active
-
2024
- 2024-01-05 AU AU2024200074A patent/AU2024200074B2/en active Active
- 2024-11-25 US US18/958,082 patent/US20250230214A1/en active Pending
-
2025
- 2025-10-20 AU AU2025252658A patent/AU2025252658A1/en active Pending
- 2025-12-24 JP JP2025279747A patent/JP2026053559A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250230214A1 (en) | 2025-07-17 |
| IL298786A (en) | 2023-02-01 |
| BR112022025019A2 (pt) | 2022-12-27 |
| AU2025252658A1 (en) | 2025-11-13 |
| US20220017591A1 (en) | 2022-01-20 |
| ECSP23002960A (es) | 2023-03-31 |
| JP2026053559A (ja) | 2026-03-25 |
| US20240025958A1 (en) | 2024-01-25 |
| AU2021290997A1 (en) | 2023-02-09 |
| MX2022016340A (es) | 2023-01-24 |
| AU2021290997B2 (en) | 2023-10-12 |
| AU2021290997C1 (en) | 2024-01-04 |
| US11795205B2 (en) | 2023-10-24 |
| TWI899263B (zh) | 2025-10-01 |
| WO2021255127A1 (en) | 2021-12-23 |
| CN115916813A (zh) | 2023-04-04 |
| TW202214673A (zh) | 2022-04-16 |
| AR125007A1 (es) | 2023-05-31 |
| CA3186143A1 (en) | 2021-12-23 |
| AU2024200074B2 (en) | 2025-11-27 |
| JP2023530335A (ja) | 2023-07-14 |
| KR20230024994A (ko) | 2023-02-21 |
| JP7797423B2 (ja) | 2026-01-13 |
| AU2024200074A1 (en) | 2024-01-25 |
| CR20230015A (es) | 2023-02-17 |
| EP4168434A1 (en) | 2023-04-26 |
| US12187774B2 (en) | 2025-01-07 |
| CO2023000038A2 (es) | 2023-01-16 |
| CN115916813B (zh) | 2026-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003578A1 (es) | Fusiones heterodiméricas de relaxina y usos de las mismas | |
| CL2022000300A1 (es) | Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252) | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
| CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| BR112012029577A2 (pt) | polipeptídeos helicoidais randômicos prolina/alanina biossintéticos e seus usos. | |
| ECSP099401A (es) | Polipeptidos heterologos il-17a/f y usos terapeuticos de los mismos | |
| CL2025000804A1 (es) | Inserción de anti-tfr:gaa y anti-cd63:gaa para el tratamiento de la enfermedad de pompe. | |
| MX2022008771A (es) | Metodos y composiciones de muteinas de il2 sesgadas. | |
| BR112012006501A8 (pt) | Polipeptídios e usos dos mesmos | |
| AR086476A2 (es) | Metodos de produccion de una proteina de interes heterologa en una celula, para aumentar la productividad celular especifica de una proteina de interes de membrana o secretada en una celula, para aumentar la eficacia de transfeccion de una celula que expresa una proteina de interes de membrana o secretada en una celula y para identificar un modulador de la funcion de proteina con dominio start, vectores de expresion, celulas, proteinas, composiciones farmaceuticas y sus usos | |
| AR030236A1 (es) | Moléculas similares a il-17 y usos de las mismas | |
| BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
| GEAP202516650A (en) | Stabilized pre-fusion hmpv fusion proteins | |
| BR112023025331A2 (pt) | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso | |
| AR013528A1 (es) | PROTEíNA-2 QUIMIOTÁCTICA MONOCíTICA (MCP-2) HUMANA AMINO TERMINALMENTE TRUNCADA, MOLÉCULA DE ADN QUE LA CODIFICA, VECTOR DE EXPRESIoN Y CÉLULA HUÉSPED CORRESPONDIENTES, PROCESO RECOMBINANTE PARA PREPARAR DICHAS PROTEíNAS, USO DE DICHAS PROTEíNAS PARA LA FABRICACIoN DE UN MEDICAMENTO uTIL PARA LA TER | |
| BR112022006923A2 (pt) | Polipeptídeos recombinantes para localização celular regulável | |
| CL2021001209A1 (es) | Constructos de suministro para transcitosis y métodos relacionados | |
| BR112022019510A2 (pt) | Variantes de beta-glucocerebrosidase para uso no tratamento de doença de gaucher | |
| BR112023003526A2 (pt) | Proteínas de fusão de coronavírus imunogênicos e métodos relacionados | |
| BR112018077225A2 (pt) | proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas | |
| AR026571A1 (es) | Genes del musgo de la physcomitrella patens que codifican proteinas que participan en la sintesis de los acidos grasos poliinsaturados y lipidos | |
| CR20170507A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos. | |
| BR112021019139A2 (pt) | Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry |